Antibody response in patients admitted to the hospital with suspected SARS-CoV-2 infection: results from a multicenter study across Spain
Fuentes, A. ; Serrano-Conde, E. ; Roldán, C. ; Benito-Ruesca, R. (Universidad de Zaragoza) ; Mejías, G. ; Sampedro, A. ; March-Roselló, G. ; Fernández-Natal, I. ; Esperalba, J. ; Rodríguez, M.J. ; Martínez de Aguirre, P. ; Salas, C. ; Roc, M.L. ; Soria, L.M. ; Parra-Grande, M. ; Montero, M.D. ; Fernández-Roblas, R. ; Franco-Álvarez de Luna, F. ; Lozano, C. ; García, F.
Resumen: Aim: To evaluate the serological response against SARS-CoV-2 in a multicenter study representative of the Spanish COVID pandemic.
Methods: IgG and IgM + IgA responses were measured on 1466 samples from 1236 Spanish COVID-19 patients admitted to the hospital, two commercial ELISA kits (Vircell SL, Spain) based on the detection of antibodies against the viral spike protein and nucleoprotein, were used.
Results: Approximately half of the patients presented antibodies (56.8% were IgM + IgA positive and 43.0% were IgG positive) as soon as 2 days after the first positive PCR result. Serological test positivity increased with time from the PCR test, and 10 days after the first PCR result, 91.5% and 88.0% of the patients presented IgM + IgA and IgG antibodies, respectively.
Conclusion: The high values of sensitivity attained in the present study from a relatively early period of time after hospitalization support the use of the evaluated serological assays as supplementary diagnostic tests for the clinical management of COVID-19.
Idioma: Inglés
DOI: 10.1007/s10096-020-04139-5
Año: 2021
Publicado en: EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES 40 (2021), 1343–1349
ISSN: 0934-9723
Factor impacto JCR: 5.103 (2021)
Categ. JCR: MICROBIOLOGY rank: 49 / 138 = 0.355 (2021) - Q2 - T2
Categ. JCR: INFECTIOUS DISEASES rank: 41 / 96 = 0.427 (2021) - Q2 - T2
Factor impacto CITESCORE: 6.7 - Medicine (Q1)
Factor impacto SCIMAGO: 1.205 - Medicine (miscellaneous) (Q1) - Infectious Diseases (Q1)
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Área Microbiología (Dpto. Microb.Ped.Radio.Sal.Pú.)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
Exportado de SIDERAL (2023-05-18-14:03:17)
Visitas y descargas
Methods: IgG and IgM + IgA responses were measured on 1466 samples from 1236 Spanish COVID-19 patients admitted to the hospital, two commercial ELISA kits (Vircell SL, Spain) based on the detection of antibodies against the viral spike protein and nucleoprotein, were used.
Results: Approximately half of the patients presented antibodies (56.8% were IgM + IgA positive and 43.0% were IgG positive) as soon as 2 days after the first positive PCR result. Serological test positivity increased with time from the PCR test, and 10 days after the first PCR result, 91.5% and 88.0% of the patients presented IgM + IgA and IgG antibodies, respectively.
Conclusion: The high values of sensitivity attained in the present study from a relatively early period of time after hospitalization support the use of the evaluated serological assays as supplementary diagnostic tests for the clinical management of COVID-19.
Idioma: Inglés
DOI: 10.1007/s10096-020-04139-5
Año: 2021
Publicado en: EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES 40 (2021), 1343–1349
ISSN: 0934-9723
Factor impacto JCR: 5.103 (2021)
Categ. JCR: MICROBIOLOGY rank: 49 / 138 = 0.355 (2021) - Q2 - T2
Categ. JCR: INFECTIOUS DISEASES rank: 41 / 96 = 0.427 (2021) - Q2 - T2
Factor impacto CITESCORE: 6.7 - Medicine (Q1)
Factor impacto SCIMAGO: 1.205 - Medicine (miscellaneous) (Q1) - Infectious Diseases (Q1)
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Área Microbiología (Dpto. Microb.Ped.Radio.Sal.Pú.)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. Exportado de SIDERAL (2023-05-18-14:03:17)
Enlace permanente:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Artículos > Artículos por área > Microbiología
Registro creado el 2021-03-10, última modificación el 2023-05-19